Form 4: Day One Biopharmaceuticals Acquired by Servier

Director J. Scott Garland reports the disposition of equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Summary

• Director J. Scott Garland disposed of all remaining equity interests in Day One Biopharmaceuticals, Inc. (DAWN) on April 23, 2026.
• The disposition follows the successful completion of the merger agreement with Servier Pharmaceuticals LLC.
• All outstanding stock options and restricted stock units (RSUs) held by the director were canceled and converted into the right to receive cash consideration.
• The merger consideration was set at $21.50 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the finalization of a previously announced merger.

Positives

• Successful completion of the merger transaction provides liquidity to shareholders at the $21.50 offer price.
• All unvested equity awards held by the director were accelerated and fully vested immediately prior to the merger effective time.

Negatives

• The company ceases to be an independent publicly traded entity following the merger.

Risks

• No ongoing risks as the company is now a wholly owned subsidiary of Servier Pharmaceuticals.

Future Outlook

The company is now a wholly owned subsidiary of Servier Pharmaceuticals, and no further public guidance or forward-looking statements are expected from the former independent entity.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of consolidation in the biopharmaceutical sector, where larger global players like Servier are acquiring specialized firms to bolster their oncology and rare disease pipelines.

Comparison to Industry Standards

• The $21.50 per share acquisition price represents a standard exit strategy for mid-cap biotech firms following clinical development milestones.
• The acceleration of unvested equity upon a change-in-control is consistent with standard executive compensation practices in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Employees and directors see the vesting and conversion of equity awards.

Next Steps

• Delisting of Day One Biopharmaceuticals common stock from public exchanges.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, Merger, Acquisition, Servier Pharmaceuticals, Form 4, Insider Transaction